Effect of ulcerative colitis treatment on transforming growth factor β1 in plasma and rectal mucosa

Regulatory Peptides

Volumn 113, Issue 1-3, 2003, Pages 57-61

  Wiercińska Drapało, Alicja ^a   Flisiak, Robert ^a   Prokopowicz, Danuta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cytokines; Inflammatory bowel diseases; TGF 1; Treatment

Indexed keywords

AMINOSALICYLIC ACID; PREDNISONE; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTUM MUCOSA; ULCERATIVE COLITIS;

EID: 0037447804     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(02)00300-2     Document Type: Article

References (29)

1. Beck P.L., Podolsky D.K. Growth factors in inflammatory bowel disease. Inflamm. Bowel Dis. 5:1999;44-60.
2. Fiocchi C. IBD: etiology and pathogenesis. Gastroenterology. 115:1998;182-205.
3. Zimmerman C.M., Padgett R.W. Transforming growth factor β signaling mediators and modulators. Gene. 249:2000;17-30.
4. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor β in human disease. N. Engl. J. Med. 342:2000;1350-1358.
5. Kitani A., Fuss I.J., Nakamura K., Schwartz O.M., Usui T., Strober W. Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta 1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J. Exp. Med. 192:2000;41-52.
6. Monteleone G., Kumberova A., Croft N.M., McKenzie C., Steer H.W., MacDonald T.T. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108:2001;601-609.
7. Babyatsky M.W., Rossiter G., Podolsky D.K. Expression of transforming growth factors α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology. 110:1996;975-984.
8. Dignass A., Podolsky D.K. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor β Gastroenterology. 105:1993;1323-1332.
9. Sturm A., Schulte C., Schatton R., Becker A., Cario E., Goebell H.et al. Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 12:2000;445-450.
10. McKaig B.C., Hughes K., Tighe P.J., Mahida Y.R. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am. J. Physiol., Cell Physiol. 282:2002;172-182.
11. Meyers S., Sachar D.B., Present D.H., Janowitz H.D. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo controlled double blind, dose-ranging clinical trial. Scand. J. Gastroenterol. 23(suppl. 148):1988;29-35.
12. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N. Engl. J. Med. 317:1987;1625-1629.
13. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis. BMJ. 2:1955;1041-1048.
14. 1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine. 12:2000;677-681.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
16. 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U. S. A. 90:1993;770-774.
17. Seder R.A., Marth T., Sieve M.C., Strober W., Letterio J.J., Roberts A.B.et al. Factors involved in the differentiation of TGF-beta producing cells from naive CD4+T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. J. Immunol. 160:1998;5719-5728.
18. Mourelle M., Salas A., Guarner F., Crespo E., Garcia-Lafuente A., Malagelada J.R. Stimulation of transforming growth factor beta-1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology. 114:1998;519-526.
19. 2 concentration. Prostaglandins Other Lipid Mediat. 58:1999;159-165.
20. 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 66:1998;1014-1020.
21. 1 develop progressive renal disease. Lab. Invest. 74:1996;991-1003.
22. Singer A.J., Clark R.A.F. Cutaneous wound healing. N. Engl. J. Med. 341:1999;738-746.
23. Lawrance I.C., Maxwell L., Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm. Bowel Dis. 7:2001;226-236.
24. 1 receptor type II mutation in ulcerative colitis associated neoplasms. Gastroenterology. 112:1997;40-45.
25. Grainger D.J., Mosedale D.E., Metcalfe J.C. TGF-β in blood: a complex problem. Cytokine Growth Factor Rev. 11:2000;133-145.
26. Bitton A., Peppercorn M.A., Antonioli D.A., Niles J.L., Shah S., Bousvaros A.et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 120:2001;13-20.
27. Hahm K.B., Im Y.H., Parks T.W., Park S.H., Markowitz S., Jung H.Y.et al. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut. 49:2001;164-165.
28. Sambuelli A., Diez R.A., Sugai E., Boerr L., Negreira S., Gil A.et al. Serum transforming growth factor-beta 1 levels increase in response to successful anti-inflammatory therapy in ulcerative colitis. Aliment. Pharmacol. Ther. 14:2000;1443-1449.
29. Whiting C.V., Williams A.M., Claesson M.H., Bregenholt S., Reimann J., Bland P.W. Transforming growth factor-beta messenger RNA and protein in murine colitis. J. Histochem. Cytochem. 49:2001;727-738.